{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:17:24Z","timestamp":1790702244086,"version":"4.1.0"},"reference-count":71,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oral tetracyclines have been used in clinical practice for over 60\u00a0years. One of the most common indications for use of oral tetracyclines is for treatment of adult outpatients with skin and soft infections (SSTIs), including acute bacterial skin and skin structure infections (ABSSSIs). The 2014 Infectious Diseases Society of America (IDSA) skin and soft tissue guideline strongly recommends sulfamethoxazole\/trimethoprim, clindamycin, and tetracyclines as oral treatment options for patients with purulent SSTIs, especially when methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> is of clinical concern. Despite the long\u2010standing use of tetracyclines, practice patterns indicate that they are often considered after other guideline\u2010concordant oral options for the treatment of patients with SSTIs. Clinicians may therefore be less familiar with the clinical data associated with use of commercially available tetracycline agents for treatment of patients with SSTI. This review summarizes the literature on the use of oral tetracyclines (ie, doxycycline, minocycline, and omadacycline) for the treatment of adult patients with SSTIs. As part of this review, we describe their common mechanisms of resistance, susceptibility profiles against common SSTI pathogens, pharmacokinetics and pharmacodynamics, and comparative clinical data.<\/jats:p>","DOI":"10.1002\/phar.2625","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T05:11:46Z","timestamp":1632460306000},"page":"915-931","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline"],"prefix":"10.1002","volume":"41","author":[{"given":"Monique R.","family":"Bidell","sequence":"first","affiliation":[{"name":"Department of Pharmacy Massachusetts General Hospital Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Albany College of Pharmacy and Health Sciences Albany New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz977"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.12.004"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"},{"key":"e_1_2_8_5_1","first-page":"23","article-title":"Gram\u2010negative bacteria as emerging pathogens affecting mortality in skin and soft tissue infections","volume":"1","author":"Ioannou P","year":"2018","journal-title":"Hippokratia"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx232"},{"key":"e_1_2_8_7_1","unstructured":"Healthcare\u2010Associated Infections\u2014Community Interface (HAIC): Emerging Infections Program (EIP) Network Report InvasiveStaphylococcus aureus 2016 Updated: February 13 2020.https:\/\/www.cdc.gov\/hai\/eip\/pdf\/2016\u2010MRSA\u2010Report\u2010508.pdf"},{"key":"e_1_2_8_8_1","unstructured":"BACTRIM\u2122 sulfamethoxazole and trimethoprim DS (double strength) tablets and tablets USP Package Insert.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/017377s068s073lbl.pdf"},{"key":"e_1_2_8_9_1","unstructured":"CLEOCIN HYDROCHLORIDE Package Insert.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050162s085lbl.pdf"},{"key":"e_1_2_8_10_1","unstructured":"ZYVOX\u00ae(linezolid) injection (linezolid) tablets (linezolid) for oral suspension Package Insert.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021130s016 021131s013 021132s014lbl.pdf"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171125"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1446939"},{"key":"e_1_2_8_13_1","unstructured":"SIVEXTRO (tedizolid phosphate) for injection for intravenous use and SIVEXTRO (tedizolid phosphate) tablet for oral use.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205435s000lbl.pdf"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-00279-0"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.08.035"},{"key":"e_1_2_8_16_1","unstructured":"NUZYRA (omadacycline) for injection for intravenous use and NUZYRA (omadacycline) tablets for oral use Package Insert.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9120905"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"a025387","DOI":"10.1101\/cshperspect.a025387","article-title":"Tetracycline antibiotics and resistance","volume":"4","author":"Grossman TH","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01257-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.023"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.6.763"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/598510"},{"key":"e_1_2_8_24_1","volume-title":"Streptococcus pyogenes: Basic Biology to Clinical Manifestations [Internet]","author":"Cattoir V","year":"2016"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.11.010"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx432"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00117-14"},{"key":"e_1_2_8_29_1","first-page":"167","article-title":"An update on tetracyclines","volume":"2","author":"Shlaes DM","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.3389\/fmicb.2019.02546","article-title":"In vitro activity and heteroresistance of omadacycline against clinical Staphylococcus aureus isolates from China reveal the impact of omadacycline susceptibility by branched\u2010chain amino acid transport system II carrier protein, Na\/Pi cotransporter family protein, and fibronectin\u2010binding protein","volume":"10","author":"Bai B","year":"2019","journal-title":"Front Microbiol"},{"key":"e_1_2_8_31_1","unstructured":"Clinical and Laboratory Standards Institute (CLSI).Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100 (ISBN 1\u201056238\u2010838\u2010X [Print]; ISBN 1\u201056238\u2010839\u20108 [Electronic]). Clinical and Laboratory Standards Institute 950 West Valley Road Suite 2500 Wayne Pennsylvania 19087 USA;2018."},{"key":"e_1_2_8_32_1","unstructured":"European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 11.0 valid from 2021\u201001\u201001.https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_11.0_Breakpoint_Tables.pdf"},{"key":"e_1_2_8_33_1","unstructured":"Antibacterial Susceptibility Test Interpretive Criteria (FDA).https:\/\/www.fda.gov\/drugs\/development\u2010resources\/antibacterial\u2010susceptibility\u2010test\u2010interpretive\u2010criteria"},{"key":"e_1_2_8_34_1","first-page":"56","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY Antimicrobial Surveillance Programme","volume":"2019","author":"Huband MD","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.11.013"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01043-17"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.06.016"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02488-19"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00018-17"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.022"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.2.239"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.03.014"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01422-17"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00843-4"},{"issue":"2","key":"e_1_2_8_47_1","first-page":"746","article-title":"Effects of rifampicin on the pharmacokinetics of doxycycline","volume":"5","author":"Garraffo R","year":"1987","journal-title":"Pathol Biol"},{"key":"e_1_2_8_48_1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050795s005lbl.pdf"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198815060-00001"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.3.462"},{"key":"e_1_2_8_51_1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050649023lbl.pdf"},{"key":"e_1_2_8_52_1","unstructured":"VillanoSJ TzanisE TanakaSK.In vitro protein binding with omadacycline a first in class aminomethylcycline antibiotic [poster no. 5180]. 2016. American Society of Microbiology Microbe Annual Meeting; Boston."},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02263-19"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.814"},{"key":"e_1_2_8_55_1","unstructured":"Nuzyra (omadacycline) prescribing information;2019.https:\/\/www.accessdata.fda.gov\/drugs.atfdadocs\/label\/2018\/209816_209817lbl.pdf"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1973145852"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx039"},{"key":"e_1_2_8_58_1","unstructured":"BowkerKE NoelAR MacGowanAP.Antibacterial effect of minocycline with or without rifampicin on MRSA strains studied in an in vitro pharmacokinetic model. In: Programs and Abstracts of the Forty fifth Interscience Conference on Antimicrobial Agents and Chemotherapy Washington DC 2005. Abstract A\u2010443 p. 16. American Society for Microbiology Washington DC USA."},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02058-19"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-19"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02368-16"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv178"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1086\/429628"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00262-07"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00206-07"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED.171.6.504"},{"key":"e_1_2_8_67_1","first-page":"711","article-title":"The comparative efficacy of minocycline and penicillin\u2010V in Staphylococcus aureus skin and soft tissue infections","volume":"5","author":"Keeney RE","year":"1979","journal-title":"Cutis"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.003"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz396"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02411-16"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2625","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:57:21Z","timestamp":1761047841000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/phar.2625"],"URL":"https:\/\/doi.org\/10.1002\/phar.2625","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"assertion":[{"value":"2021-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}